Terns Pharmaceuticals (NASDAQ:TERN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Terns Pharmaceuticals (NASDAQ:TERN) from a sell rating to a hold rating in a research report sent to investors on Saturday.

A number of other equities research analysts also recently commented on the company. Jefferies Financial Group reissued a “buy” rating and issued a $70.00 target price on shares of Terns Pharmaceuticals in a report on Wednesday, December 10th. UBS Group upgraded shares of Terns Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 4th. Truist Financial boosted their price objective on shares of Terns Pharmaceuticals from $35.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Citizens Jmp upped their target price on shares of Terns Pharmaceuticals from $35.00 to $57.00 and gave the stock a “market outperform” rating in a research report on Thursday, December 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $55.80.

Terns Pharmaceuticals Price Performance

TERN opened at $37.79 on Friday. The business has a 50 day simple moving average of $38.68 and a 200-day simple moving average of $21.59. The stock has a market capitalization of $3.92 billion, a P/E ratio of -36.69 and a beta of -0.28. Terns Pharmaceuticals has a 12 month low of $1.87 and a 12 month high of $48.26.

Insider Activity at Terns Pharmaceuticals

In related news, CEO Amy L. Burroughs sold 68,749 shares of Terns Pharmaceuticals stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $37.07, for a total transaction of $2,548,525.43. Following the completion of the transaction, the chief executive officer directly owned 288,976 shares in the company, valued at $10,712,340.32. The trade was a 19.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Emil Kuriakose sold 1,155 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total value of $44,548.35. Following the sale, the insider owned 50,365 shares in the company, valued at approximately $1,942,578.05. This trade represents a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 141,243 shares of company stock worth $5,311,090 over the last quarter. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Terns Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Morgan Stanley lifted its holdings in Terns Pharmaceuticals by 4.7% in the 4th quarter. Morgan Stanley now owns 7,945,608 shares of the company’s stock valued at $321,003,000 after purchasing an additional 356,513 shares in the last quarter. Commodore Capital LP purchased a new position in shares of Terns Pharmaceuticals during the third quarter valued at approximately $42,807,000. Vanguard Group Inc. boosted its position in Terns Pharmaceuticals by 21.1% during the fourth quarter. Vanguard Group Inc. now owns 5,523,948 shares of the company’s stock worth $223,167,000 after acquiring an additional 964,031 shares during the last quarter. Franklin Resources Inc. boosted its position in Terns Pharmaceuticals by 113.8% during the fourth quarter. Franklin Resources Inc. now owns 2,731,312 shares of the company’s stock worth $110,345,000 after acquiring an additional 1,453,849 shares during the last quarter. Finally, Lord Abbett & CO. LLC purchased a new stake in Terns Pharmaceuticals in the 4th quarter worth approximately $109,581,000. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.